MARIZYME (MRZM) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 57 133 sessions, April 12, 2024 to April 14, 2025
- Largest daily move
- +1150% close of January 15, 2025
- 1-year change
- -99.5% closing prices, April 12, 2024 to April 14, 2025
- 1-month change
- -90% closing prices, March 14, 2025 to April 14, 2025
Company Description
MARIZYME (OTC: MRZM) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $39.5K.
MRZM has declined 99.5% over the past year. The last closing price was $0.0003.
For FY2023, MARIZYME reported revenue of $646K with net income of -$69.5M and diluted earnings per share of -$1.53. The company operates at a net profit margin of -10767.8%.
This page collects what Stock Titan holds for MRZM, including price data, latest news, SEC filings, financial highlights, and short interest trends.
Stock Performance
MARIZYME (MRZM) closed at $0.0003 on April 14, 2025. Over the past 12 months, the price has lost 99.5%.
MRZM Metrics & Rankings
Price returns through April 14, 2025. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
MARIZYME has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 4 with negative movement. Key topics include fda approval, acquisition. View all MRZM news →
SEC Filings
MARIZYME has filed 1 recent SEC filing, including 1 Form 8-K. The most recent filing was submitted on April 17, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all MRZM SEC filings →
Financial Highlights
MARIZYME generated $646K in revenue in FY2023, retaining a 70.9% gross margin, operating income reached -$34.1M (-5278.1% operating margin), and net income was -$69.5M, reflecting a -10767.8% net profit margin. Diluted earnings per share stood at -$1.53. The company generated -$4.7M in operating cash flow. The current ratio was 0.04, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in MARIZYME (MRZM) currently stands at 7 shares. Since November 2025, short interest has increased by 133.3%.
Days to Cover History
Days to cover for MARIZYME (MRZM) currently stands at 1000.0 days, up 14185.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.
MRZM Company Profile & Sector Positioning
MARIZYME (MRZM) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing MRZM often look at related companies in the same sector, including NAVIDEA BIOPHARMS INC (NAVB), SYROS PHARMACEUTICALS INC (SYRS), ARIDIS PHARMACEUTICAL INC (ARDS), PAXMEDICA INC (PXMD), and TRACON PHARMS INC (TCON). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MRZM's relative position within its industry.